Rare-Disease Studies: Models, Endpoints and Clinical Sustainability
Rare diseases force us to rethink how evidence is generated. Numbers are small, heterogeneity is high, and natural history is often incomplete. Yet this is precisely where the rigour of a programme is measured BioPharma: in the ability to build study models credible, choose endpoint that say something true for patients and regulators, and demonstrate clinical sustainability beyond the initial announcement. At Technoscience, we approach rare diseases with a simple rule: “fewer patients” does not mean “less methodology”. It means a different methodology, one that is more careful and more transparent.
Before the trial: natural history and registries that matter
In rare diseases, the time spent understand the natural history is not wasted time: it is the foundation of any efficacy assessment. A well-designed registry is not a list of names; it is a structure that defines diagnostic criteria, phenotypes, progression times, key events and repeatable measurements. Without this map, the effect of a therapy risks being confused with the natural fluctuation of the disease. This is why we integrate clinical registries, biobanks, telemedicine data and, where relevant, continuous digital measurements: it is the only way to provide context for numbers that, on their own, cannot be “big”.
Study models: when the classics are not enough
Randomisation remains the gold standard for evidence, but in rare diseases it is not always practical or ethical. Hence the careful use of adaptive designs (with pre-specified rules), master protocol and platform trial when biology links multiple subtypes; alternatively, external controls derived from quality registries, with transparent matching and declared limitations. Under some conditions, it makes sense to use N-of-1 or crossover to measure the intra-patient effect. Where signals are complex and series are small, Bayesian help integrate prior knowledge and current data, but only if assumptions are made explicit and shared with the regulator. The key word is one: pre-specification. Any flexibility not declared in advance becomes fragility later.
Explore the topics
Endpoints that really matter (and how to choose them)
The endpoint are not a formality. In rare diseases they must be sensitive, clinically significant and measurable within the available timeframe. Sometimes a surrogate is acceptable (enzymes, accumulation biomarkers, quantitative imaging) if there is a reasonable plausibility that anticipates a clinical benefit. At other times, you need functional outcomes: motor, respiratory, cardiac and neurocognitive function, PRO/HRQoL with instruments validated for that population. The typical mistake is to choose measures that are too “pure” for the laboratory or, conversely, generic indicators that do not change within the timescale of a realistically feasible study. The middle ground is a endpoint panel with a clear hierarchy: the primary who decides, the secondary that explain, the explorers that prepare for the future.
Real-world data and telemedicine: from the centre to real life
In rare-disease settings, the real-world data are not a fallback: they are the natural continuation of the evidence-generation process. Telemedicine, sensors, electronic health records and post-approval registries make it possible to follow small cohorts over the long periods needed to determine whether a benefit persists. The measures digital continuous (mobility, sleep-wake rhythm, arrhythmic burden, respiratory patterns) add granularity and turn the quarterly visit into a continuous narrative. But they are worthwhile only if there is quality: stable definitions, plans for allocation clear, management of the drift of sensors, audit trail.
Patient engagement: participation that changes science
In rare diseases, patients and associations are co-authors of the pathway. From defining endpoints (what counts as “benefit” in everyday life) to procedure feasibility (how many visits, how many hours, what burdens), through to return of results, their voice genuinely changes the design and the retention. Involvement is not folklore: it improves adherence, reduces missing data, makes useful quality-of-life outcomes. It is also a lever for practical ethics: we ask for what is needed, not what “is always requested”.
Clinical sustainability: beyond the p-value
A rare-disease therapy is sustainable when it integrates without breaking care pathways, when the requirements of monitoring are realistic, when the safety profile can be managed in practice and when the clinical value also makes sense for payers and HTA. This is why we focus early on resource use, need for expert centres, training, associated devices, and we hypothesise adoption scenarios: it is not enough for it to work; it must be able to work in the real world. The commitments post-approval (confirmatory studies, mandatory registries, surveillance) are not an ancillary burden: they are part of the commitment.
How we work when the disease is rare
At the outset, we ask for three certainties. One diagnosis clear operational definition (criteria and tests), a natural history minimum on which to anchor choices and sizing, and a precise understanding of endpoint measurable within the realistic timeframe of the study. We help build or strengthen the registries, to choose designs compatible with biology and ethics, and map from the outset the regulatory pathway most appropriate (Orphan, conditional pathways) so as not to postpone issues that will inevitably resurface. Where needed, we design RWD collection plans and telemedicine to extend observation beyond the trial perimeter.
Choose Technoscience!
If you are designing a study that requires samples and data of verified quality, request a fit check: in a short call, we align the clinical or industrial question, sample availability, ethical requirements and quality standards; if the scope is sound, we plan a pathway from responsible access to validation without wasting time.
Frequently Asked Questions
The questions you ask us most often
We start from natural history and by the clinical need. If a surrogate is well linked to the mechanism, it can anticipate benefit; otherwise, you need functional outcomes and PRO validated. The endpoint hierarchy must be established in advance, with timelines compatible with disease progression.
They can be when randomisation is impractical or ethically questionable. But the control registry must have quality: comparable criteria, prospective or well-documented data collection, matching transparent. It is nevertheless a choice to discuss early with the regulator.
They are often part of theregulatory commitment in rare diseases: they consolidate evidence on long-term efficacy and safety, measure resource use and quality of life, and can inform HTA and payers in reimbursement reviews.